HyperMed, Inc.
HCID Member | Medical Devices & Tech
41 Second Avenue
Burlington, MA 01803 USA
phone: 781-229-5900
fax: 781-229-5910
Symbol Private
Founded 1997
Employees 20
www.hypermed-inc.com
Research Sector Medical Devices & Tech
Summary Description
Imaging products used to diagnose diabetic foot complications and peripheral arterial disease
Management
Mark Carbeau, President, CEO and Member, Board of Directors; Rick Lifsitz, M.B.A., CTO and Member, Board of Directors; Jim Sheppard, VP of Manufacturing; Kevin T. Schomacker, Ph.D., VP of Clinical Research and Regulatory
Keywords
Diabetes, blood sugar, diabetic, metabolic, insulin, Imaging, diagnostics, Diabetes, blood sugar, diabetic, metabolic, insulin, imaging products, PAD, medical device, peripheral disease, j2008b

Comment | Printable Version | Jun. 16, 2008
If you work for HyperMed, Inc. and want to update this profile, click here

Description
HyperMed is developing and commercializing medical hyperspectral imaging products. The company has created the first hyperspectral imaging platform for use in medical and surgical applications. HyperMed's first product, OxyVu(TM), initially targets the screening, diagnosis, and monitoring of diabetic foot disease and peripheral arterial disease (PAD). HyperMed's OxyVu provides previously unavailable information about tissue signatures (spectra) to assist in diagnosis and therapy
Products / Services
HyperMed's lead product, the OxyVu imager, will provide a powerful and important solution to current unmet medical needs in accurately diagnosing and treating diabetic foot complications and peripheral arterial disease. With a moderately-priced system and a single-use disposable, OxyVu is designed to provide rapid information in the hospital, clinic or physician office. Over two hundred fifty clinical studies in patients with diabetic foot disease and peripheral arterial disease have confirmed the utility of the quantitative measures of tissue health provided by OxyVu.
Market / Customers
Over the past ten years, research has demonstrated that OxyVu has broad medical applications, and preliminary work has led to the first target -- diabetic foot complications and peripheral arterial disease (PAD). In the US, over 150,000 lower extremity amputations are performed annually in diabetics. The diabetic foot disease market is assessed at over $10 billion.
Competitors / Substitutes / Alternatives
Current clinical testing (e.g. ankle brachial index, pulse volume recordings, and laser Doppler flowmetry) measure blood flow to tissue and cannot assess oxygenation status. Transcutaneous oxygen measurements are time consuming and highly subjective, and do not provide any information about the spatial variability across the foot.
Strategy
HyperMed has commercialize OxyVu as the first viable, non-invasive tissue assessment tool targeting diabetic foot complications and peripheral arterial disease and seeks to continues to build a product portfolio of OxyVu products, with subsequent extension to include detection of the onset of shock, the assessment of the progression of diabetes, and the evaluation of tissue margins for residual cancer during resective surgery; obtain broad FDA approval for OxyVu products and establish reimbursement for OxyVu measurements and calibration disposables; partner with leading therapeutic companies for joint marketing and sales; develop channels for sales and distribution of OxyVu systems & disposables to generate a strong revenue platform from instrument installation & recurring revenues from disposables; generate a strong revenue platform from instrument installation & recurring revenues from disposables.
Funding
HyperMed has leveraged founders' capital, government grant funding and more recently venture capital to perform clinical research, product development, and intellectual property protection activities. Greenwich Biotech Capital is the primary source of venture capital.
Status
HyperMed has received 510(k) approval from the FDA to market OxyVu, intended to measure oxygenation status in tissue. For more information, please visit www.hypermed-inc.com.


2008-09-07-4205